NCT07152821View on ClinicalTrials.gov

Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcinoma

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

834

Participants

Timeline

Start Date

November 30, 2025

Primary Completion Date

December 31, 2028

Study Completion Date

June 30, 2029

Conditions
Colorectal Cancer
Interventions
OTHER

Best Supportive Care

Measures designed to provide palliation of symptoms and improve quality of life as much as possible

DRUG

Balstilimab

450mg IV every 3 weeks

DRUG

Botensilimab

75mg IV every 6 weeks x 4 doses

Sponsors

Collaborators (1)

Agenus Inc.
All Listed Sponsors
collaborator

Agenus Inc.

INDUSTRY

collaborator

Australasian Gastro-Intestinal Trials Group

NETWORK

collaborator

UNICANCER

OTHER

lead

Canadian Cancer Trials Group

NETWORK